A multicenter, randomized, double-blind, placebo and escitalopram controlled trial of the safety and efficacy of BMS-562086 [pexacerfont] in the treatment of outpatients with major depressive disorder
Phase of Trial: Phase I/II
Latest Information Update: 14 Dec 2007
At a glance
- Drugs Escitalopram; Pexacerfont
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2007 The expected completion date for this trial is now 1 Oct 2007.
- 14 Dec 2007 Status change from in progress to completed.
- 31 Jul 2007 Status changed from recruiting to in progress.